Table 1.

Baseline characteristics in the intention-to-treat population

Variable	FOLFOX plus bevacizumab (n=177)	FOLFOXIRI plus bevacizumab (n=172)
Age (years)	59 (53–65)	61 (54–66)
Sex
Male	119 (67.2%)	118 (68.6%)
Female	58 (32.8%)	54 (31.4%)
ECOG performance status
0	85 (48.0%)	81 (47.1%)
1	92 (52.0%)	91 (52.9%)
Tumour localisation
Colon	108 (61.0%)	113 (65.7%)
Rectum	48 (27.1%)	38 (22.1%)
Colorectal	21 (11.9%)	21 (12.2%)
Site of primary tumour
Left colon	137 (77.4%)	119 (69.2%)
Right colon	39 (22.0%)	48 (28.0%)
Both	1 (0.6%)	5 (2.9%)
Site of metastases
Liver only	62 (35.0%)	62 (36.1%)
Multiple sites	115 (65.0%)	110 (64.0%)
Metastatic sites
≤1	65 (36.7%)	68 (39.5%)
>1	112 (63.3%)	104 (60.5%)
Presentation
Synchronous	167 (94.4%)	160 (93.0%)
Metachronous	10 (5.7%)	12 (7.0%)
Prior treatment
Surgery	55 (31.0%)	59 (34.3%)
Radiotherapy	4 (2.3%)	5 (2.9%)
Chemotherapy*	7 (4.0%)	9 (5.2%)
CEA levels
≤5 ng/mL	8 (4.5%)	16 (9.3%)
>5 ng/mL	169 (95.5%)	156 (90.7%)
RAS status
Mutated†	84 (47.5%)	85 (49.4%)
Wildtype	88 (49.7%)	85 (49.4%)
Data not available	5 (2.8%)	2 (1.2%)
PI3K status
Mutated	17 (9.6%)	26 (15.1%)
Wildtype	159 (89.8%)	146 (84.9%)
Data not available	1 (0.6%)	0 (0%)
BRAF status
Mutated	17 (9.6%)	16 (9.3%)
Wildtype	160 (90.4%)	156 (90.7%)
MSI
MSI high	1 (0.6%)	2 (1.2%)
MSI low	7 (4.0%)	8 (4.7%)
MSS	156 (88.1%)	156 (90.7%)
Data not available	13 (7.3%)	6 (3.5%)

Data are no (%) or median (IQR).

*Adjuvant or neoadjuvant setting.

†Mutated in KRAS (exon 2, 3 or 4) or NRAS (exon 2, 3, or 4).

CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin and irinotecan; MSI, microsatellite instability; MSS, microsatellite stable.